* Offer at $31/shr expires Aug 7, unless extended
July 10 Bristol-Myers Squibb Co on
Tuesday launched its tender offer to buy all outstanding shares
of biotechnology company Amylin Pharmaceuticals Inc.
Bristol-Myers said last month it would pay $31 per share for
Amylin, helping it extend its portfolio of diabetes treatments
with the addition of drugs Byetta and Bydureon.
The offer to buy all of Amylin's common stock will expire at
5:00 p.m. New York time on Aug. 7, unless extended,
Bristol-Myers said in a statement.